Researchers clash over AAA screening's worth
Two European studies published on the same day have reached opposite conclusions about the cost-effectiveness of ultrasound screening exams for abdominal aortic aneurysm.
Two European studies published on the same day have reached opposite conclusions about the cost-effectiveness of ultrasound screening exams for abdominal aortic aneurysm.
Researchers in the U.K. came to a positive conclusion about the exam's cost-effectiveness based on nearly 70,000 subjects enrolled in the Multicenter Aneurysm Screening Study (MASS). A cost/benefit analysis showed average per-life-year gains below the National Health Service's benchmark of £25,000. Danish investigators, on the other hand, reported negative findings using a mathematical model and data from the literature and the Danish Vascular Registry to estimate costs and outcomes for a hypothetical population of Danish men aged 65 from screening to death. Their estimates showed the cost of screening per quality adjusted life year was $71,160, well beyond the local accepted benchmark of $49,530. Both studies were published online June 26 in the British Medical Journal.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
